Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Safety and Efficacy of MBX-102/JNJ-39659100 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy
Sponsor: Gilead Sciences
Terminated
MBX-102 did not meet the target efficacy profile of HbA1c change.
Other terminated trials from Gilead Sciences
Other Type 2 Diabetes Mellitus trials with similar outcome
A PHASE2 clinical study on Type 2 Diabetes Mellitus, this trial is terminated or withdrawn. The trial is conducted by Gilead Sciences and has accumulated 9 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Oct 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Dec 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bangalore, India , Burbank, United States , Chennai, India , Hyderabad, India , Indore, India , Jaipur, India , Karnāl, India , Kochi, India , Las Vegas, United States , Los Angeles, United States and 8 more locations